Alice Wiltshire joined the National Horizon Scanning Centre (NHSC) as a research associate (Horizon Analyst) in March 2010. The NHSC provides early warning to the Department of Health of new and emerging technologies that may require evaluation, consideration of clinical and cost impact, or modification of clinical guidance.
HPC state registered Clinical Scientist (Immunology), 2009.
Member of the Association of Clinical Biochemistry.
MSc Pathological Sciences, University of Sheffield Hallam 2007.
BSc(Hons) Immunology, University of Edinburgh 2003.
Alice Wiltshire graduated from the University of Edinburgh in 2003 with a 2.1 BSc honours degree in Immunology. From 2003 to 2005, she worked as a MRC research technician in colon cancer genetics. Her project investigated the colorectal cancer risk associated with MUTYH gene mutations in the Scottish population. The work is published in the American Journal of Human Genetics.
In 2009 Alice qualified as a HPC state registered Clinical Scientist in Immunology with a Masters in Pathological Sciences, after completing a 4 year training programme at Sheffield Teaching Hospitals.
Alice joined the NHSC in March 2010. As part of her work she conducts secondary research reviewing the literature on new and emerging pharmaceutical technologies that are likely to be launched in the NHS within the next three years. This involves writing briefing reports which appraise pharmaceutical technologies on the basis of safety, efficacy, clinical and cost effectiveness. These assist key national policy-makers, including the National Institute for Health and Clinical Excellence (NICE) drug appraisal topic selection process.
Farrington SM, Tenesa A, Barnetson R, Wiltshire A, et al. (2005). Germline Susceptibility to Colorectal Cancer Due to Base-Excision Repair Gene Defects. American Journal of Human Genetics, 77(1):112-9.